Metastat Inc · OTC:MTST
Metastat — Rodman & Renshaw 2014 Annual Global Investment Conference
23 slides from Metastat's conference presentation, Sep 10, 2014
Slide 1: Rodman & Renshaw 2014 Annual Global Investment Conference
Rodman & Renshaw 2014 Annual Global Investment Conference MetasStat, Inc. Corporate Presentation September 10, 2014 @MetaStat
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered by the safe har
Slide 3: Investment Highlights
Investment Highlights Unique Technology Based on the Novel Understanding of the Key Drivers of Systemic Metastasis * Epigenetic understanding of the overwhelming complexity of the metastatic process; * This complexity highlights the need for mechanism-based diagnostics; * The Mena protein isoforms a
Slide 4: Recent Developments
Recent Developments Closed $5.7 million Private Placement of Common Stock * Conversion of $3.3 million of promissory notes to common stock; * Key hires: development, commercialization, and laboratory personnel; * Opened diagnostics laboratory in Boston, MA capable of supporting commercial operations
Slide 5: Experienced senior management team
Experienced senior management team with deep understanding of the clinical, scientific, and business aspects of oncology A Oscar chief Executive + Diplomat, American Board of Surgery Bronsther, M.D. Officer and Chief + Clinical Professor of Surgery, George Washington University ‘Medlcol Officer; + F
Slide 6: Scientific and Clinical Advisory Board
Over 15 years of platform technology R&D by Scientific and Clinical team at leading academic research centers Scientific and Clinical Advisory Board Albert Einstein College of Medicine + Inventor of Metaste “The uith and Burton P.Resrick Chain Translational Research + Pioneer in developing microscop
Slide 7: The Metastatic Cancer Problem
The Metastatic Cancer Problem Systemic metastasis is responsible for 90% of solid tumor cancer related deaths Only a fraction of epithelial-based solid tumors (depending upon the tumor micro- environment and the expression of Mena isoforms) are biologically capable of metastatic spread; * 30-35% of
Slide 8: The Mena Protein Story
The Mena Protein Story Mena is an embryonic protein, which in utero participates in the maturation of the central and peripheral nervous system; Post partum, expression of Mena is heavily suppressed — beings have only trace amounts of Mena; healthy human Our fundamental discovery is that epithelial-
Slide 9: Metastatic Cancer Cell Opening the Blood Vessel Wall
Metastatic Cancer Cell Opening the Blood Vessel Wall Metastatic cell opening the blood vessel wall @MetaStat
Slide 10: The MetaSite: Capturing the Tumor MicroEnvironment
The MetaSite: Capturing the Tumor MicroEnvironment The Window or Portal Where Systemic Metastasis Takes Place: Three cells in apposition + Red Metastatic Cell (Mena +) ~ Pan-Mena MAB + Blue Endothelial Cell - CD31 MAB + Brown Macrophage — CD68 MAB Triple Immuno- histochemical Stain @MetaStat
Slide 11: Publications in Peer-reviewed Scientific Journals
Publications in Peer-reviewed Scientific Journals a Giinicat Developmental Cancer Research [ MetaStat's research team has published over 25 articles in 10* leading US and international science journals @MetaStat
Slide 12: Encouraging Breast Cancer Clinical Validation
Encouraging Breast Cancer Clinical Validation Studies * 3 positive trials consisting of a total of 585 patients; Weenicyy-naa ° 481 patient study published online in Journal of the National Cancer Institute (JNCI)*; * Highly prognostic for ER+, HER2- (~60% of all breast cancer patients). * 2 trials
Slide 13: The MetaStat Solution
The MetaStat Solution * Minimize treatment for patients with favorable tumors; MetaStat’s products have the potential to: ‘+ Maximally treat patients with aggressive tumors; * Facilitate personalized and targeted cancer therapy; * Benefit both patients and the healthcare system. + Near-term revenue
Slide 14: Diagnostic Product Portfolio
Diagnostic Product Portfolio MetaStat is developing a platform with multiple diagnostic applications : ~ NEE — Diagnostics Breast ‘A diagnostic that predicts the probability of Breast” metastasis based on the density of “Metasites" Met Immunohistochemistry test Diagnostic Breast A diagnostic platfor
Slide 15: Our Diagnostic Assays
Our Diagnostic Assays We have been able to exploit this novel understanding to bring two distinctive Mena- based, products to the market: + MetaSite Breast — an immunohistochemistry test that exploits our discovery that a 3 cell micro-anatomical unit in women with breast cancer is the portal by whic
Slide 16: Market Opportunity: Breast Cancer Diagnostics
Market Opportunity: Breast Cancer Diagnostics ASCO & NCCN recommend breast cancer diagnostic testing. The current genomic tests on the market (est. to be ~$250-$275MM) have limited applicability; + Inherent problems with tests based on bio-statistically derived algorithms; + Only applicable to ~60%
Slide 17: A $1.7B annual market opportunity
A $1.7B annual market opportunity for MetaStat’s diagnostic products in the U.S. Number ofnew | Addressable | Potentialcases | Market Size Product cases per year Market , % per year ($ mm) MetaSite Breast 232,000 60 139,200 $348 MenaCalc - Breast 232,000 40 92,800 $232 MenaCalc- Lung 226,160 40 90,4
Slide 18: Tremendous Worldwide Breast Cancer Market
Tremendous Worldwide Breast Cancer Market Breast cancer is the 2" most common cancer in the world and, by far the most frequent cancer among women with an estimated 1.67 million new cases diagnosed in 2012 (25% of all cancers). + Breast cancer ranks as the 5" cause of death overall (522,000 deaths).
Slide 19: MetaSite and MenaCalc fit into existing clinical workflow
MetaSite and MenaCalc will easily fit into existing clinical workflow with a 3-5 Day turn-around time on penises ise we ee = ee “ee . Sn _ — von | se a veut Teameapant pee att Sn = we ee =) =F “coe co Physician Pathology tab | , iene — “Sac vostnes! mop +... = sn i @MetaStat
Slide 20: Regulatory Pathway
Regulatory Pathway Two Pathways to Market * Lab Derived Test (LDT) regulated under CLIA (Clinical Laboratory Improvement Amendments); * In vitro Diagnostic (IVD) regulated by FDA, 510(k) submission and approval. Preferred Approach is to Offer LDT from Central Laboratory * Faster to market, less cost
Slide 21: Reimbursement
Reimbursement * MetaSite Breast and MenaCale diagnostic tests are eligible for 3rd party reimbursement under already established medical billing codes = CPT Code 8836: Morphometric analysis, tumor immunohistochemistry, quantitative or semi-quantitative, each antibody; using computer- assisted techno
Slide 22: MetaStat has Strong IP Positions
MetaStat has Strong IP Positions Broad Intellectual Property Position; * 13 patents filed; + 3 patents issued. Amster, Rothstein, and Ebenstein, LLP & Morgan, Lewis, and Bockius, LLP Oversee our Patent Portfoli + Freedom to Operate. MetaStat Retains World-wide Rights to Develop and Commercialize Mol
Slide 23: Investment Highlights
Investment Highlights Unique Technology Based on the Novel Understanding of the Key Drivers of Systemic Metastasis * Epigenetic understanding of the overwhelming complexity of the metastatic process; * This complexity highlights the need for mechanism-based diagnostics; * The Mena protein isoforms a
MetaStat — Rodman & Renshaw 2014 Annual Global Investment Conference on 6ix